Recently, IL-6 blockade was found to promote tumor immunity through activation of the immunostimulatory IL-12 pathway, while abrogating the toxicity of checkpoint blockade, thus decoupling tumor immunity from autoimmune toxicity (145). This evidence concerns the gene IL6 and neoplasm.